文献速递乳腺癌

卡培他滨在早期乳腺癌中的作用:随机对照试验的荟萃分析

Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials.
PubMed 文献 · Eur J Cancer · 2017-03-27

该荟萃分析纳入8项随机对照试验共9302例早期乳腺癌患者,评估标准化疗联合或不联合卡培他滨的疗效。在未选择人群中,卡培他滨未影响无病生存(HR 0.99,p=0.93)或总生存(HR 0.90,p=0.36)。在标准化疗基础上加用卡培他滨可改善三阴性乳腺癌的无病生存(HR 0.72 vs 非三阴性1.01,交互p=0.02),但增加3/4级腹泻(OR 2.33)和手足综合征(OR 8.08)。

要点

  • 在未选择的早期乳腺癌患者中,卡培他滨未显著改善无病生存或总生存。
  • 在标准化疗基础上加用卡培他滨可改善三阴性乳腺癌的无病生存(HR 0.72 vs 非三阴性1.01)。
  • 卡培他滨增加3/4级腹泻(OR 2.33)和手足综合征(OR 8.08)及治疗中断(OR 3.80)。

核心结论

  • 在标准化疗基础上加用卡培他滨似乎可改善三阴性乳腺癌的无病生存和总生存,但增加不良事件,与其已知毒性特征一致。

研究设计与样本

  • 荟萃分析,检索PubMed和主要会议论文集,纳入比较新辅助或辅助化疗联合或不联合卡培他滨的随机对照试验,共8项研究9302例患者。

主要发现

  • 在未选择患者中,卡培他滨未影响无病生存(HR 0.99,p=0.93)或总生存(HR 0.90,p=0.36)。
  • 卡培他滨加用于标准化疗对比替代标准化疗时,无病生存存在显著差异(HR 0.92 vs 1.62,交互p=0.002)。
  • 在标准化疗基础上加用卡培他滨,三阴性乳腺癌对比非三阴性乳腺癌的无病生存显著改善(HR 0.72 vs 1.01,交互p=0.02)。
  • 荟萃回归显示,在三阴性乳腺癌患者比例更高的研究中,加用卡培他滨与总生存改善相关(R=-0.967,p=0.007)。
  • 卡培他滨增加3/4级腹泻(OR 2.33,p<0.001)和手足综合征(OR 8.08,p<0.001),并导致更频繁的治疗中断(OR 3.80,p<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Capecitabine is an effective therapy for metastatic breast cancer. Its role in early breast cancer is uncertain due to conflicting data from randomised controlled trials (RCTs). METHODS: PubMed and major conference proceedings were searched to identify RCTs comparing standard chemotherapy with or without capecitabine in the neoadjuvant or adjuvant setting. Hazard ratios (HRs) for disease-free survival (DFS) and overall survival (OS), as well as odds ratios (ORs) for toxicities were extracted or calculated and pooled in a meta-analysis. Subgroup analysis compared triple-negative breast cancer (TNBC) to non-TNBC and whether capecitabine was given in addition to or in place of standard chemotherapy. Meta-regression was used to explore the influence of TNBC on OS. RESULTS: Eight studies comprising 9302 patients were included. In unselected patients, capecitabine did not influence DFS (hazard ratio [HR] 0.99, p = 0.93) or OS (HR 0.90, p = 0.36). There was a significant difference in DFS when capecitabine was given in addition to standard treatment compared with in place of standard treatment (HR 0.92 versus 1.62, interaction p = 0.002). Addition of capecitabine to standard chemotherapy was associated with significantly improved DFS in TNBC versus non-TNBC (HR 0.72 versus 1.01, interaction p = 0.02). Meta-regression showed that adding capecitabine to standard chemotherapy was associated with improved OS in studies with higher proportions of patients with TNBC (R = -0.967, p = 0.007). Capecitabine increased grade 3/4 diarrhoea (odds ratio [OR] 2.33, p < 0.001) and hand-foot syndrome (OR 8.08, p < 0.001), and resulted in more frequent treatment discontinuation (OR 3.80, p < 0.001). CONCLUSION: Adding capecitabine to standard chemotherapy appears to improve DFS and OS in TNBC, but increases adverse events in keeping with its known toxicity profile.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Natori A, Ethier JL, Amir E, et al. Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials. Eur J Cancer. 2017. PMID: 28355581. doi:10.1016/j.ejca.2017.02.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。